Impact of the introduction of formal D2 lymphadenectomy for gastric cancer in a Western setting

Alexandre Brind’Amour, MD
Jean-Pierre Gagné, MD
Jean-Charles Hogue, PhD
Éric Poirier, MD

The results have been presented as an oral presentation at the 2018 conference of the Société Française de Chirurgie (Paris, September 2018).

Accepted Mar. 17, 2020

Correspondence to:
É. Poirier
Centre Hospitalier Universitaire de Québec — Université Laval
1050 chemin Ste-Foy
Québec QC G1S 4L8
ricpoirier@me.com

DOI: 10.1503/cjs.019919

Background: Two members from an academic tertiary hospital went to the National Cancer Institute in Tokyo, Japan, to learn how to perform an adequate D2 lymphadenectomy and to then introduce this technique in the surgical care of patients undergoing surgery for gastric cancer at a Western hospital. We aimed to compare the perioperative outcomes and long-term survival of Western patients who underwent gastric resection, performed by these 2 surgeons, before and after the surgeons’ short-course technical training in Japan.

Methods: We conducted a retrospective comparative study of all patients (n = 27 before training and n = 79 after training) who underwent gastric resection for cancer by the same 2 surgeons between September 2007 and December 2017 at the Centre Hospitalier Universitaire de Québec — Université Laval (Québec, Canada). We collected data on patient demographic, clinical, surgical, pathological and treatment characteristics, as well as long-term survival and complications.

Results: In the post-training group, the number of sampled lymph nodes was higher (median 33 v. 14, p < 0.0001), but this increase did not result in a higher number of histologically positive lymph nodes (p = 0.35). The rate of complications was lower in the post-training group (15.2% v. 48.2%, p = 0.002). The hospital stay was shorter in the post-training group (11 [standard deviation (SD) 7] v. 23 [SD 45] d, p = 0.03). The median survival was higher in the post-training group (47 v. 29 mo, p = 0.03).

Conclusion: These results suggest that a short-course technical training in D2 lymphadenectomy, completed in Japan, improved lymph node sampling, decreased postoperative complications and improved survival of patients undergoing surgery for gastric cancer in a Western setting.

Contexte : Deux membres d’un centre hospitalier universitaire en soins tertiaires se sont rendus à l’Institut national du cancer de Tokyo, au Japon, pour apprendre à effectuer une lymphadénectomie de type D2 et ensuite intégrer cette technique aux interventions chirurgicales visant à contrer un cancer de l’estomac dans un hôpital occidental. L’objectif était de comparer les issues périzaïopathologiques et la survie à long terme des patients qui ont subi une gastrectomie réalisée par les 2 chirurgiens, avant et après leur formation technique de courte durée au Japon.

Méthodes : Nous avons mené une étude rétrospective comparative portant sur tous les patients (n = 27 avant la formation, et n = 79 après la formation) qui, entre septembre 2007 et décembre 2017, ont subi une gastrectomie pour un cancer réalisé par les 2 chirurgiens au Centre hospitalier universitaire de Québec — Université Laval (Québec, Canada). Nous avons recueilli des données démographiques, cliniques, chirurgicales et pathologiques ainsi que des données sur les traitements, la survie à long terme et les complications.

Résultats : Dans le groupe de patients opérés après la formation, un plus grand nombre de ganglions lymphatiques a été prélevé (médiane 33 c. 14; p < 0.0001), mais cette augmentation n’était pas accompagnée d’un plus grand nombre d’analyses histologiques positives (p = 0.35). Le taux de complications était plus faible dans ce groupe (15.2% c. 48.2%; p = 0.002), et l’hospitalisation, plus courte (11 jours [écart type (E.-T.) 7] c. 23 jours [E.-T. 45]; p = 0.03). De plus, la durée de survie médiane était plus élevée dans ce groupe (47 mois c. 29 mois; p = 0.03).

Conclusion : Ces résultats laissent croire qu’une courte formation technique sur la lymphadénectomie de type D2, réalisée au Japon, améliore le prélèvement de ganglions lymphatiques, diminue les complications postopératoires et prolonge la survie des patients qui subissent une chirurgie pour un cancer de l’estomac en Occident.
Gastric cancer is the fifth most common cancer and the third leading cause of cancer death worldwide. In Canada, it was estimated that 4100 Canadians were diagnosed with gastric cancer in 2019, and 1950 died from it. Complete surgical excision is the only curative treatment for operable gastric cancer.

Five-year survival for gastric cancer in Japan ranges from 92% for patients in stage IA to 35% for patients in stage III B. In comparison, 5-year survival in the United States ranges from 71% for patients in stage IA to 14% for patients in stage III B. In Eastern Asia, total or subtotal gastrectomy with D2 lymphadenectomy is the standard of care for the treatment of gastric cancer, with low rates of perioperative mortality and morbidity.

Methods

Study design and patients

We conducted a retrospective study of all consecutive patients, operated on by the 2 surgeons trained in Japan, who underwent gastric resection for cancer between September 2007 and December 2017 at the Centre Hospitalier Universitaire de Québec — Université Laval, an academic hospital in Québec, Canada. The study was approved by the ethics committee of the Centre Hospitalier Universitaire de Québec — Université Laval. The need for individual consent was waived by the committee.

We included patients with a pathological diagnosis of gastric adenocarcinoma, undergoing gastrectomy for cancer by 1 of the 2 surgeons trained in Japan, with a complete data set. The exclusion criteria were patients undergoing palliative resection and patients with a second primary cancer. The primary outcome was overall survival. The secondary outcomes were lymph node count and perioperative complications.

Training in Japan

Two members of our group of surgeons went to Japan in November 2013 for a 1-month short course of specialized technical training at the Cancer Institute Hospital of the Japanese Foundation of Cancer Research (Tokyo, Japan) and the Hyogo Cancer Center (Osaka, Japan). The objectives of this training were to learn the technique of Japanese D2 lymphadenectomy and to become familiar with the perioperative care of gastric cancer patients in Japan. This was an observership. The 2 surgeons observed 3 cases each day for 3 weeks, for a total of 45 cases.

Surgery

The extent of the gastrectomy was determined by the location of the tumour, with a targeted proximal margin of 5 cm. Before training, the type of lymphadenectomy used in our hospital was variable, ranging from D1 to D1+. All the patients in this study who underwent surgery after the training had a formal D2 lymphadenectomy according to the recommendations of the Japanese Gastric Cancer Association. The lymph nodes were found in the specimens by the pathologists.

Postoperative care

Many changes in the postoperative care of patients were made after the training in Japan. Patients were placed on an enhanced recovery program, with omission of a routine nasogastric tube and introduction of a liquid diet on postoperative day 1. Feeding tube jejunostomy was placed only for selected patients with severe preoperative...
malnutrition, compared with the more routine use of this approach pre-training. The consistency of the diet was progressed according to patient tolerance, resolution of postoperative ileus and nutritionist recommendations. Patients were encouraged to ambulate by the evening following the surgery, and all catheters were removed as soon as possible.

**Follow-up**

The routine follow-up after gastrectomy for cancer is 5 years. If no recurrence occurred during those 5 years, the patients were discharged from the hospital clinic and were followed by their general practitioner, who returned the patients to the clinic in case of suspicion of recurrence. For patients living far from the hospital, follow-up could be entrusted to a local hospital. We censored follow-up as of November 15, 2019. Because the patients were operated over 2 different time periods, we censored the follow-up in the pre-training group to the longest available follow-up in the post-training group. Therefore, the exposure time was the same in the 2 groups.

**Data collection**

We collected data prospectively in a database, including patient demographics, comorbidities, body mass index, tumour characteristics, clinical tumour site, lymph node involvement, metastasis (cTNM) stage, neoadjuvant or adjuvant treatments, use of diagnostic laparoscopy and cytology of the peritoneal lavage. Operative data included the procedure (total or subtotal gastrectomy, open or laparoscopic procedure), reconstruction, the inclusion of a feeding tube jejunostomy, operative time and estimated blood loss. Postoperative data included time to resume diet, length of hospital stay and postoperative complications according to the Clavien–Dindo scale.20 Pathologic data included surgical margins, lymph node count and tumour stage, including pathological TNM (pTNM) or post-therapy TNM (yTNM). Deaths and morbidity were obtained from the follow-up hospital chart.

**Statistical analysis**

Continuous variables were tested for normal distribution using the Kolmogorov–Smirnov test. Normally distributed continuous variables were presented as means (standard deviations [SDs]) and analyzed using the Student t test. Non-normally distributed variables were presented as medians (ranges) and analyzed using the Kruskal–Wallis test. Categorical data were presented as frequencies and analyzed using the Fisher exact test. Survival was determined using the Kaplan–Meier method and analyzed using the log-rank test. All analyses were performed using SAS 9.3 (SAS Institute). Two-sided p values < 0.05 were considered statistically significant.

**Results**

**Patient characteristics**

Table 1 presents the characteristics of the patients. The post-training group showed a higher proportion of men (p = 0.03), and the tumour location pattern was different (p = 0.04). There were no significant differences between the 2 groups regarding other characteristics.

**Operative characteristics**

Table 2 presents the operative data of the patients. In the post-training group, the number of reported lymph

| Variable                      | All  | Pre-training | Post-training | p value |
|-------------------------------|------|--------------|---------------|---------|
| Sex                           | 0.03 | 0.03         | 0.03          |         |
| Male                          | 74 (69.8) | 14 (51.8) | 60 (75.9) |         |
| Female                        | 32 (30.2) | 13 (48.2) | 19 (24.1) |         |
| Age, mean ± SD, yr            | 69.5 ± 12.2 | 69.9 ± 11.7 | 68.0 ± 12.4 | 0.51    |
| Comorbidities†                | 0.57 | 0.57         | 0.57          |         |
| Hypertension                  | 45 (42.5) | 12 (44.4) | 11 (13.9) |         |
| Diabetes mellitus             | 20 (18.9) | 3 (11.1) | 19 (49.4) |         |
| Cardiovascular disease        | 27 (25.5) | 9 (33.3) | 17 (21.5) |         |
| Renal failure                 | 4 (3.8) | 1 (3.7) | 1 (1.3) |         |
| Presentation†                 | 0.41 | 0.41         | 0.41          |         |
| Obstructive lesion            | 12 (11.3) | 1 (3.7) | 11 (13.3) |         |
| Anemia                        | 52 (49.1) | 13 (48.2) | 39 (49.4) |         |
| Abdominal pain                | 23 (21.7) | 6 (22.2) | 17 (21.5) |         |
| Weight loss                   | 46 (43.4) | 14 (61.9) | 32 (40.5) |         |
| Other                         | 19 (17.9) | 4 (14.8) | 15 (19.3) |         |
| Tumour location               | 0.04 | 0.04         | 0.04          |         |
| Gastroesophageal junction     | 10 (9.4) | 0          | 10 (12.7) |         |
| Proximal                      | 19 (17.9) | 2 (7.4) | 17 (21.5) |         |
| Body                          | 37 (34.9) | 12 (44.5) | 25 (31.7) |         |
| Distal                        | 37 (34.9) | 12 (44.5) | 25 (31.7) |         |
| Linitis                       | 3 (2.8) | 1 (3.6) | 2 (2.5) |         |

Note: SD = standard deviation.
*Unless indicated otherwise.
†The same patient may have more than one value.
nodes was higher (median 33 v. 14, \(p < 0.0001\)), but it did not result in a higher number of positive lymph nodes found at histological examination (median 2 v. 1, \(p = 0.35\)), meaning that there was no stage migration. There was no significant difference in the numbers of node-positive cases (51.9% v. 67.1%, \(p = 0.17\)). Pre-training, 37.0% of the patients met the requirement for nodal dissection (16 lymph nodes), compared with 91.1% of patients post-training (\(p < 0.0001\)), showing that the quality standards changed after training. In the

| Variable                                      | No. (%) of patients* |
|-----------------------------------------------|-----------------------|
|                                              | All \(n = 106\)        | Pre-training \(n = 27\) | Post-training \(n = 79\) | \(p\) value |
| T (pathological)                              |                       |                        |                          |             |
| T1a                                           | 10 (9.4)              | 4 (14.8)               | 6 (7.6)                  | 0.70        |
| T1b                                           | 14 (13.2)             | 2 (7.4)                | 12 (15.2)                |             |
| T2                                            | 11 (10.4)             | 4 (14.8)               | 7 (8.9)                  |             |
| T3                                            | 44 (41.5)             | 11 (40.7)              | 33 (41.8)                |             |
| T4a                                           | 21 (19.8)             | 5 (18.5)               | 16 (20.3)                |             |
| T4b                                           | 6 (5.7)               | 1 (3.7)                | 5 (6.3)                  |             |
| Sampled lymph nodes, median (range)           | 29 (2–96)             | 14 (2–92)              | 33 (2–96)                | < 0.0001    |
| Positive lymph nodes, median (range)          | 2 (0–22)              | 1 (0–22)               | 2 (0–21)                 | 0.35        |
| Met the minimal requirement for lymph node dissection (≥ 16) | 82 (77.4)             | 10 (37.0)              | 72 (91.1)                | < 0.0001    |
| N (pathological)                              |                       |                        |                          |             |
| N0                                            | 39 (36.8)             | 13 (48.2)              | 26 (32.9)                | 0.39        |
| N1                                            | 25 (23.6)             | 4 (14.8)               | 20 (25.3)                |             |
| N2                                            | 22 (20.8)             | 6 (22.2)               | 17 (21.5)                |             |
| N3a                                           | 15 (14.2)             | 2 (7.4)                | 13 (16.5)                |             |
| N3b                                           | 5 (4.7)               | 2 (7.4)                | 3 (3.8)                  |             |
| Node-positive cases                           | 67 (63.2)             | 14 (51.9)              | 53 (67.1)                | 0.17        |
| M (pathological)                              |                       |                        |                          | 0.99        |
| M0                                            | 99 (93.4)             | 25 (92.6)              | 74 (93.7)                |             |
| M1                                            | 7 (6.6)               | 2 (7.4)                | 5 (6.3)                  |             |
| Grade                                         |                       |                        |                          | 0.09        |
| 1                                             | 15 (14.2)             | 3 (11.1)               | 12 (15.2)                |             |
| 2                                             | 37 (34.9)             | 14 (51.9)              | 23 (29.1)                |             |
| 3                                             | 54 (50.9)             | 10 (37.0)              | 44 (55.7)                |             |
| Positive for HER2                              | 9 (8.5)               | 1 (3.7)                | 8 (10.1)                 | 0.44        |
| Diagnostic laparoscopy                        | 43 (40.6)             | 12 (44.4)              | 31 (39.2)                | 0.66        |
| Surgery                                       |                       |                        |                          | 0.04        |
| Open                                          | 67 (63.2)             | 12 (44.4)              | 55 (69.6)                |             |
| Laparoscopic                                   | 39 (36.8)             | 15 (55.6)              | 24 (30.4)                |             |
| Conversion                                    | 1 (0.9)               | 1 (3.7)                | 0                        |             |
| Gastrectomy                                   |                       |                        |                          | 0.12        |
| Total                                         | 50 (47.2)             | 9 (33.3)               | 41 (51.9)                |             |
| Subtotal                                      | 56 (52.8)             | 18 (66.7)              | 38 (48.1)                |             |
| Splenectomy                                   | 26 (24.5)             | 0                     | 26 (32.9)                | 0.0002      |
| Colectomy                                     | 1 (0.9)               | 0                     | 1 (1.3)                  | 0.99        |
| Pancreatectomy                                 | 8 (7.6)               | 1 (3.7)                | 7 (8.9)                  | 0.68        |
| Roux-en-Y reconstruction                      | 87 (82.1)             | 13 (48.2)              | 74 (93.7)                | < 0.0001    |
| Gastric anastomosis†                           |                       |                        |                          | 0.08        |
| Sutured                                       | 8 (7.6)               | 4 (14.8)               | 4 (5.1)                  |             |
| Stapled                                       | 85 (80.2)             | 15 (55.6)              | 70 (88.6)                |             |
| Intracorporeal                                 | 1 (0.9)               | 0                     | 1 (1.3)                  |             |
| Jejuno-jejunal anastomosis†                    |                       |                        |                          | < 0.0001    |
| Sutured                                       | 9 (8.5)               | 3 (11.1)               | 6 (7.6)                  |             |
| Stapled                                       | 72 (67.9)             | 10 (37.0)              | 62 (78.5)                |             |
| Intracorporeal                                 | 0                     | 0                     | 0                        |             |
| Feeding tube jejunostomy                      | 23 (21.7)             | 16 (59.3)              | 7 (8.9)                  |             |
| Surgical margins, positive                    | 4 (3.8)               | 0                     | 4 (5.1)                  | 0.57        |
post-training group, a higher proportion of splenectomies was performed (33% v. 0%, \( p = 0.0002 \)), as well a higher proportion of Roux-en-Y reconstructions (94% v. 48%, \( p < 0.0001 \)) and stapled jejuno-jejunal anastomoses (\( p < 0.0001 \)). There was no difference in the rate of diagnostic laparoscopies between the 2 groups. There was no difference between the 2 groups in the rate of positive surgical margins, operating time and blood loss. The approach to perioperative chemotherapy remained the same, but fewer patients received adjuvant radiotherapy in the post-training group (4% v. 19%, \( p = 0.02 \)). The rate of complications was lower in the post-training group (15% v. 48%, \( p = 0.002 \)). The length of hospital stay was shorter in the post-training group (11 [SD 7] v. 23 [SD 45] days, \( p = 0.03 \)).

### Table 2. Patient operative characteristics (part 2 of 2)

| Variable                              | No. (%) of patients*                                                                 |
|---------------------------------------|--------------------------------------------------------------------------------------|
|                                      | All (n = 106)  | Pre-training (n = 27)  | Post-training (n = 79)  | \( p \) value |
| Operating time, mean ± SD, min        | 269 ± 71         | 284 ± 68               | 264 ± 71               | 0.24           |
| Blood loss, mean ± SD, mL             | 367 ± 277        | 305 ± 307             | 385 ± 264             | 0.22           |
| Cases with complications              | 25 (23.6)        | 13 (48.2)             | 12 (15.2)             | 0.002          |
| Proximal leak                         | 1 (0.9)          | 0                    | 1 (1.3)               |               |
| Jejuno-jejunal leak                    | 1 (0.9)          | 0                    | 1 (1.3)               |               |
| Infection                             | 4 (3.8)          | 2 (7.4)               | 2 (2.5)               |               |
| Pneumonia                             | 8 (7.6)          | 2 (7.4)               | 6 (7.6)               |               |
| Acute coronary syndrome               | 5 (4.7)          | 3 (11.1)              | 2 (2.5)               |               |
| Urinary infection                     | 1 (0.9)          | 1 (3.7)               | 0                     |               |
| Thrombosis                            | 3 (2.8)          | 1 (3.7)               | 2 (2.5)               |               |
| Incisional hernia                     | 2 (1.9)          | 1 (3.7)               | 1 (1.3)               |               |
| 30-day mortality                      | 3 (2.8)          | 2 (7.4)               | 1 (1.3)               |               |
| Reoperation for complication          | 1 (0.9)          | 1 (3.7)               | 0                     |               |
| Length of stay, mean ± SD, d          | 16 ± 26          | 23 ± 45               | 11 ± 7                | 0.03           |
| Neoadjuvant chemotherapy              | 43 (40.6)        | 10 (37.0)             | 33 (41.8)             | 0.82           |
| ECF                                   | 25 (23.6)        | 8 (29.6)              | 17 (21.5)             |               |
| EOF                                   | 1 (0.9)          | 0                    | 1 (1.3)               |               |
| EOX                                   | 3 (2.8)          | 1 (3.7)               | 2 (2.5)               |               |
| DCF                                   | 7 (6.6)          | 0                    | 7 (8.9)               |               |
| D-FOX                                 | 6 (5.7)          | 0                    | 6 (7.6)               |               |
| Adjuvant radiotherapy                 | 8 (7.6)          | 5 (18.5)              | 3 (3.8)               | 0.02           |
| Adjuvant chemotherapy                 | 30 (28.3)        | 7 (25.9)              | 23 (29.1)             | 0.81           |

Note: DCF = Docetaxel, Cisplatin, 5-Fluorouracil; D-FOX = Docetaxel, Oxaliplatin, 5-Fluorouracil; ECF = Epirubicin, Cisplatin, 5-Fluorouracil; EOF = Epirubicin, Oxaliplatin, 5-Fluorouracil; EOX = Epirubicin, Oxaliplatin, Capecitabine; HER2 = human epidermal growth factor receptor 2 protein; M = metastasis; N = lymph node involvement; SD = standard deviation; T = tumour site.
*Unless indicated otherwise.
†The same patient may have more than one value.

**Survival**

Table 3 presents the long-term survival of the patients. The median follow-up time was shorter in the post-training group (25 v. 39 months, \( p = 0.0001 \)). The median survival was higher in the post-training group (47 v. 29 months, \( p = 0.03 \)) (Figure 1). The 5-year survival was 19% and 48% in the pre- and post-training groups, respectively.

### Table 3. Patient survival

| Variable                              | All (n = 106) | Pre-training (n = 27) | Post-training (n = 79) | \( p \) value |
|---------------------------------------|--------------|----------------------|-----------------------|--------------|
| Follow-up, median (range, mo)         | 26 (1–142)   | 39 (2–142)           | 25 (1–74)             | 0.0001       |
| Median survival (mo†)                 | 39           | 29                   | 47                    | 0.026        |
| 12-month survival                     | 89 (83.9)    | 20 (74.1)            | 69 (87.3)             |              |
| 36-month survival                     | 58 (54.7)    | 15 (55.6)            | 58 (73.4)             |              |
| 60-month survival                     | 36 (33.9)    | 5 (18.5)             | 38 (48.1)             |              |

*Unless indicated otherwise.
†When considering equal follow-up between the 2 groups (i.e., censored at the longest follow-up in the post-training group) using log-rank test.

**Discussion**

The objective of the present study was to compare the perioperative outcomes and long-term survival of patients operated on by 2 surgeons before and after a short course of specialized technical training. The results suggest that an observership on D2 lymphadenectomy improved the extent of lymph node dissection and also improved the survival of gastric cancer patients in a Western setting, without compromising patient safety.
Surgery is recognized as the most important treatment option for gastric cancer, but outcomes have been disappointing in Western countries, although better survival has been reported in Eastern Asia. Differences in life habits, environment and genetics have been suggested, but Western surgeons historically performed a more limited lymphadenectomy than their Eastern Asian counterparts. In Eastern Asia, D2 lymphadenectomy is the standard of care for gastric cancer, and has been so in Japan for the last 50 years. Gastrectomy with D2 lymphadenectomy is a complex procedure associated with a steep learning curve and a high risk of postoperative morbidity and death, mainly because of splenectomy and distal pancreatectomy. Nevertheless, high-volume specialized centres can now achieve acceptable morbidity and risk. Expert surgical coaching has been described in recent literature, referring to when an expert surgeon imparts new skills or knowledge to another surgeon being coached. Its effectiveness has been shown, not only for medical students and residents, but for practising surgeons as well. Regarding expert coaching in D2 lymphadenectomy, Luna and colleagues recently reported lower morbidity and longer survival of patients who underwent D2 versus D1 lymphadenectomy after training in Japan, and highlighted the importance of appropriate training in a dedicated centre. There is also an ongoing educational project in Korea (KLASS-02-QC) that is aiming at standardizing D2 lymphadenectomy, highlighting the importance of the completeness of D2 lymphadenectomy. Another important aspect of surgeon education after residency is peer coaching, when 2 surgeons have a similar level of experience and knowledge and engage in a collaborative learning process. Peer coaching has been shown to be a good opportunity for continuous professional development for surgeons in independent practice, and peer coaching programs have already been implemented in the US. After attending the short-course training together in Japan, the 2 surgeons in this study assisted each other for most of the cases of gastrectomy and D2 lymphadenectomy, increasing each other’s exposure to the technique and contributing to an increase in the quality of the dissection. Finally, we believe that open surgery is still the gold standard approach in the Western setting, as D2 lymphadenectomy requires technical aspects that are very difficult to transpose in laparoscopy without high-volume exposure.

The postoperative care of the patients was modelled to the Japanese system and may explain, at least in part, the shorter length of stay and lower rates of postoperative complications. Early postoperative nutrition has been shown to reduce trauma-related high metabolism and help maintain the function of the intestinal barrier, hence decreasing the rate of gut-associated surgical infections. The benefits of this approach have already been demonstrated in gastric cancer patients. In the present study, the rate of complications was much lower after the training in Japan (from 48% to 15%), and we believe that standardized postoperative care played a major role in this improvement, particularly by decreasing perioperative deaths. Interestingly, more proximal tumours were treated with total gastrectomy and splenectomy in the post-training group, and more patients had pathologically positive nodes. Poorer survival would be expected in this situation, but the present study suggests the contrary. The changes in the surgical approach and postoperative care could, at least in part, explain this difference.

In Japan, the surgeons go to the pathology department after the surgery and examine the specimens themselves in order to determine the extent of lymph node sampling. In North America and Europe, as in our centre, the examination of the specimens for harvested lymph nodes is performed only by the pathologist. In the present study, the number of harvested lymph nodes was higher in the post-training group, and since the surgeons were not involved in the lymph node count, this suggests that the increase resulted from the new surgical approach applied after training.

Limitations

The present study has limitations. The sample size was small. The study spans a rather large period of time, and it is possible that changes in practice routine over time biased the results. Finally, the follow-up duration is different between the 2 groups, which could have affected the overall survival analysis. However, as gastric cancer is a lethal disease in the short term, the survival benefit (about 12 months) is significant. Prospective follow-up will be continued.
CONCLUSION

This study showed that short training in a specialized and experienced gastric cancer centre in Japan on D2 lymphadenectomy improved the extent of lymph node dissection and survival of gastric cancer patients in a Western setting. Emphasis should also be made on perioperative and postoperative care to decrease the rate of complications.

Acknowledgments: The authors acknowledge the invaluable contribution of Ann Wright, research and surgical ward nurse, for her help in data collection and maintaining the database.

Affiliations: From the Département de Chirurgie, Faculté de Médecine, Université Laval, Québec City, Que. (Brind’Amour, Gagné, Poirier); the Département de Chirurgie générale, Centre Hospitalier Universitaire de Québec, Québec City, Que. (Gagné, Poirier); and the Axe Oncologie, Centre de Recherche du Centre Hospitalier Universitaire de Québec, Université Laval, Québec City, Que. (Hogue, Poirier).

Competing interests: None declared.

Contributors: All authors conceived and designed the study, and acquired and analyzed the data. All authors wrote and critically revised the manuscript. All authors gave final approval of the article to be published.

Content licence: This is an Open Access article distributed in accordance with the terms of the Creative Commons Attribution (CC BY-NC-ND 4.0) licence, which permits use, distribution and reproduction in any medium, provided that the original publication is properly cited, the use is non-commercial (i.e., research or educational use), and no modifications or adaptations are made. See: https://creativecommons.org/licenses/by-nc-nd/4.0/

References

1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J Clin 2020;70:7-30.
2. Canadian Cancer Society, Canadian Cancer Statistics 2019. Ottawa: Canadian Cancer Society; 2019.
3. NCCN clinical practice guidelines in oncology: gastric cancer, version 4.2019, Fort Washington: National Comprehensive Cancer Network; 2019.
4. Katai H, Ishikawa T, Akazawa K, et al. Five-year survival analysis of surgically resected gastric cancer cases in Japan: a retrospective analysis of more than 100,000 patients from the nationwide registry of the Japanese Gastric Cancer Association (2001-2007). Gastric Cancer 2018;21:144-54.
5. Jim MA, Pinheiro CS, Carreira H, et al. Stomach cancer survival in the United States by race and stage (2001-2009): findings from the CONCORD-2 study. Cancer 2017;123:4994-5013.
6. Saka M, Morita S, Fukagawa T, et al. Present and future status of gastric cancer surgery. Jpn J Clin Oncol 2011;41:307-13.
7. Japanese Gastric Cancer Association. Japanese gastric cancer treatment guidelines 2014 (ver. 4). Gastric Cancer 2017;20:1-19.
8. Bonenkamp JJ, Songun I, Hermans J, et al. Randomised comparison of morbidity after D1 and D2 dissection for gastric cancer in 996 Dutch patients. Lancet 1995;345:745-8.
9. Cuschieri A, Fayers P, Fielding J, et al. Postoperative morbidity and mortality after D1 and D2 resections for gastric cancer: preliminary results of the MRC randomised controlled surgical trial. The Surgical Cooperative Group. Lancet 1996;347:905-9.
10. Degiuli M, Sasaki M, Calgaro M, et al. Morbidity and mortality after D1 and D2 gastrectomy for cancer: interim analysis of the Italian Gastric Cancer Study Group (IGCSG) randomised surgical trial. Eur J Surg Oncol 2004;30:303-308.
11. Songun I, Putter H, Kranenberg EM, et al. Surgical treatment of gastric cancer: 15-year follow-up results of the randomised nationwide Dutch D1D2 trial. Lancet Oncol 2010;11:439-49.
12. Wu CW, Hsiung CA, Lo SS, et al. Nodal dissection for patients with gastric cancer: a randomised controlled trial. Lancet Oncol 2006;7:309-15.
13. Mocellin S, McCulloch P, Kazi H, et al. Extent of lymph node dissection for adenocarcinoma of the stomach. Cochrane Database Syst Rev 2015;8:CD001964.
14. Sue-Ling H. Radical D2 gastrectomy for cancer. The case of D2 resections. Ann R Coll Surg Engl 2007;89:672-4.
15. Yarem A, de Manzoni G, Fetsch T, et al. On the road to standardization of D2 lymph node dissection in a European population of patients with gastric cancer. World J Gastrointest Oncol 2016;8:489-97.
16. Degiuli M, De Manzoni G, Di Leo A, et al. Gastric cancer: current status of lymph node dissection. World J Gastroenterol 2016;22:2875-93.
17. Yamamoto M, Rashid OM, Wong J. Surgical management of gastric cancer: the East vs. West perspective. J Gastrointest Oncol 2015;6:79-88.
18. Nitti D, Marchet A, Olivieri M, et al. D2 or non D2-lymphadenectomy in gastric cancer. Oncologia 2004;27:34-7.
19. Garg PK, Jakhetiya A, Sharma J, et al. Lymphadenectomy in gastric cancer: Contentious issues. World J Gastrointest Oncol 2016;8:294-300.
20. Clavien PA, Barkun J, de Oliveira ML, et al. The Clavien-Dindo classification of surgical complications: five-year experience. Ann Surg 2009;250:187-96.
21. Marrelli D, De Stefano A, de Manzoni G, et al. Prediction of recurrence after radical surgery for gastric cancer: a scoring system obtained from a prospective multicenter study. Ann Surg 2005;241:247-55.
22. Ferri L. Extended lymphadenectomy in gastric cancer is crucial. World J Surg 2013;37:1768-72.
23. Sasaki M, Sano T, Yamamoto S, et al. D2 lymphadenectomy alone or with para-aortic nodal dissection for gastric cancer. N Engl J Med 2008;359:453-62.
24. Bang YJ, Kim YW, Yang HK, et al. Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial. Lancet 2012;379:315-21.
25. Schmidt B, Yoon SS, D1 versus D2 lymphadenectomy for gastric cancer. J Surg Oncol 2013;107:259-64.
26. Jiang L, Yang KH, Guan QL, et al. Survival and recurrence free benefits with different lymphadenectomy for resectable gastric cancer: a meta-analysis. J Surg Oncol 2013;107:807-14.
27. Sasaki M, McCulloch P, Kinoshita T, et al. New method to evaluate the therapeutic value of lymph node dissection for gastric cancer. Br J Surg 1995;82:346-51.
28. Lee J, Lim DH, Kim S, et al. Phase III trial comparing capcitabine plus cisplatin versus capcitabine plus cisplatin with concurrent capcitabine radiotherapy in completely resected gastric cancer with D2 lymph node dissection: the ARTIST trial. J Clin Oncol 2012;30:268-73.
29. Lee JH, Ryu KW, Lee JH, et al. Learning curve for total gastrectomy with D2 lymph node dissection: cumulative sum analysis for qualified surgery. Ann Surg Oncol 2006;13:1175-81.
30. Luna A, Rebasa P, Montmany S, et al. Learning curve for D2 lymphadenectomy in gastric cancer. ISRN Surg 2013;2013:508719.
31. Bonenkamp JJ, Hermans J, Sasaki M, et al. Extended lymph-node dissection for gastric cancer. N Engl J Med 1999;340:908-14.
32. Cuschieri A, Weeden S, Fielding J, et al. Patient survival after D1 and D2 resections for gastric cancer: long-term results of the MRC randomized surgical trial. Surgical Co-operative Group. Br J Cancer 1999;79:1522-30.
33. Hartzrink HH, van de Velde CJ, Putter H, et al. Extended lymph node dissection for gastric cancer: who may benefit? Final results of the randomized Dutch gastric cancer group trial. J Clin Oncol 2004;22:2069-77.
34. Sano T, Sasaki M, Yamamoto S, et al. Gastric cancer surgery: morbidity and mortality results from a prospective randomized controlled trial comparing D2 and extended para-aortic lymphadenectomy–Japan Clinical Oncology Group study 9501. J Clin Oncol 2004;22:2767-73.
35. Degiuli M, Sasako M, Ponti A. Italian Gastric Cancer Study Group. Morbidity and mortality in the Italian Gastric Cancer Study Group randomized clinical trial of D1 versus D2 resection for gastric cancer. *Br J Surg* 2010;97:643-9.

36. Greenberg CC, Klingensmith ME. The continuum of coaching: opportunities for surgical improvement at all levels. *Ann Surg* 2015;262:217-9.

37. Greenberg JA, Jolles S, Sullivan S, et al. A structured, extended training program to facilitate adoption of new techniques for practicing surgeons. *Surg Endosc* 2018;32:217-24.

38. Kim HI, Hur H, Kim YN, et al. Standardization of D2 lymphadenectomy and surgical quality control (KLASS-02-QC): a prospective, observational, multicenter study. *BMC Cancer* 2014;14:209.

39. Greenberg CC, Ghousseini HN, Pavuluri Quamme SR, et al. A statewide surgical coaching program provides opportunity for continuous professional development. *Ann Surg* 2018;267:868-73.

40. Huang D, Sun Z, Huang J, et al. Early enteral nutrition in combination with parenteral nutrition in elderly patients after surgery due to gastrointestinal cancer. *Int J Clin Exp Med* 2015;8:13937-45.

41. Hur H, Si Y, Kang WK, et al. Effects of early oral feeding on surgical outcomes and recovery after curative surgery for gastric cancer: pilot study results. *World J Surg* 2009;33:1454-8.